Xinnan Wang

This team recently discovered that a small molecule they had originally developed to treat Parkinson’s disease can also reduce the volume of glioblastoma tumors – the most common form of aggressive brain tumor — by targeting the mitochondrial protein Miro1. They will use their Neuroscience:Translate award to study the mechanisms of the compound’s anti-tumor action and prepare to apply for investigational-new-drug status to move this discovery toward the clinic.

We will comprehensively define the gene network associated with mitochondrial dysfunction in Parkinson's disease using a cutting-edge technology, CRISPR, to understand how these nerve cells die in PD and how we can reverse the cell death to treat the disease.

Creating a center for neurodegeneration research focusing on brain maintenance and regeneration, and the role of the immune system in these processes.